LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression.
We have previously shown that mouse atherosclerosis regression involves monocyte-derived (CD68+) cell emigration from plaques and is dependent on the chemokine receptor CCR7. Concurrent with regression, mRNA levels of the gene encoding LXRalpha are increased in plaque CD68+ cells, suggestive of a functional relationship between LXR and CCR7. To extend these results, atherosclerotic Apoe-/- mice sufficient or deficient in CCR7 were treated with an LXR agonist, resulting in a CCR7-dependent decrease in plaque CD68+ cells. To test the requirement for LXR for CCR7-dependent regression, we transplanted aortic arches from atherosclerotic Apoe-/- mice, or from Apoe-/- mice with BM deficiency of LXRalpha or LXRbeta, into WT recipients. Plaques from both LXRalpha and LXRbeta-deficient Apoe-/- mice exhibited impaired regression. In addition, the CD68+ cells displayed reduced emigration and CCR7 expression. Using an immature DC line, we found that LXR agonist treatment increased Ccr7 mRNA levels. This increase was blunted when LXRalpha and LXRbeta levels were reduced by siRNAs. Moreover, LXR agonist treatment of primary human immature DCs resulted in functionally significant upregulation of CCR7. We conclude that LXR is required for maximal effects on plaque CD68+ cell expression of CCR7 and monocyte-derived cell egress during atherosclerosis regression in mice.
Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, New York, USA.
Jonathan E
JE
Feig
Ines
I
Pineda-Torra
Marie
M
Sanson
Michelle N
MN
Bradley
Yuliya
Y
Vengrenyuk
Dusan
D
Bogunovic
Emmanuel L
EL
Gautier
Daniel
D
Rubinstein
Cynthia
C
Hong
Jianhua
J
Liu
Chaowei
C
Wu
Nico
N
van Rooijen
Nina
N
Bhardwaj
Michael
M
Garabedian
Peter
P
Tontonoz
Edward A
EA
Fisher
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001013:Aorta, Thoracic / Q000276:immunology* / Q000473:pathology / Q000637:transplantation; D050197:Atherosclerosis / Q000276:immunology* / Q000473:pathology*; D002460:Cell Line; D002465:Cell Movement; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology; D000071518:Liver X Receptors; D008264:Macrophages / Q000276:immunology*; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D057093:Orphan Nuclear Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D058226:Plaque, Atherosclerotic / Q000276:immunology*; D054400:Receptors, CCR7 / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D000097382:CD68 Molecule; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D006845:Hydrocarbons, Fluorinated; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D054400:Receptors, CCR7; D013449:Sulfonamides; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C515371:Ccr7 protein, mouse; C000605213:NR1H3 protein, human; C000605214:Nr1h3 protein, mouse; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides